LOS ANGELES--(BUSINESS WIRE)--

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Investors who purchased or otherwise acquired PlasmaTech Biopharmaceuticals, Inc. shares between March 31, 2015 and June 19, 2015; and/or Abeona shares between June 22, 2015 and December 9, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the February 14, 2017 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Mako Research published a report on SeekingAlpha.com stating, "ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure." The report found that Steven H. Rouhandeh, the Company's Executive Chairman and Principal Executive Officer, was once the managing director at D. Blech & Co., a brokerage firm that was the subject of SEC investigations during the 1990s, as well as a securities class action suit that ended in a $15 million investor settlement due to claims that the firm altered the price of some biotech stocks through transactions that falsely inflated the market price of the stocks. When this information was released to the public, the value of Abeona securities fell, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170124006137/en/